On Tuesday, Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), gained 0.05% to $113.18.
Pharming Group N.V. and its partner, Hyupjin Corporation, a Seoul based South Korean specialty pharma company, declare that Hyupjin has received the marketing authorisation for RUCONEST® (recombinant human C1 inhibitor) in South Korea. RUCONEST is approved for the treatment of acute angioedema attacks in adult patients with hereditary angioedema HAE. Effectiveness was not established in HAE patients with laryngeal and oro-pharyngeal attacks. Hyupjin will now seek reimbursement for RUCONEST in South Korea.
Sijmen de Vries, CEO of Pharming, commented: “Hyupjin is a well-established and practiced company with a proven track record in South Korea. We look forward to them now extending the commercialisation of RUCONEST by providing HAE patients in South Korea with a new, safe and effective treatment to treat their HAE atttacks.”
Choon Duk Kim, General Manager of Hyupjin Corporation, said: “RUCONEST is the first approved recombinant C1 esterase inhibitor worldwide and this approval of RUCONEST will now enable us to provide the Korean HAE patients access to this most innovative way to treat their disease. We fully appreciate all the supports from Pharming Group for the approval of RUCONEST in South Korea and we look forward to getting started.”
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
Shares of PulteGroup, Inc. (NYSE:PHM), declined -0.03% to $17.80, during its last trading session.
PulteGroup, declared that it will release its fourth quarter 2015 financial results before the market opens on Thursday, January 28, 2016. The Company will hold a conference call to discuss fourth quarter results that same day at 8:30 a.m. (ET).
PulteGroup, Inc., through its auxiliaries, engages in the homebuilding business; mortgage banking operations; and title operations in the United States. The company is involved in the acquisition and development of land primarily for residential purposes; and the construction of housing on land.
Finally, Twenty-First Century Fox Inc (NASDAQ:FOX), remained flat at $27.60.
FOX News Channel (FNC) declared that the network will host its second Republican presidential primary debate on Thursday, January 28, 2016 from Des Moines, Iowa. The two-hour debate will be presented live from the Iowa Events Center at 9PM/ET on FNC, in addition to the network’s additional platforms, counting FOX News Radio, FOX News Mobile and FOXNews.com. FNC’s first Republican primary debate on August 6th delivered a record-breaking 24 million viewers and was the highest-rated non-sports cable broadcast of all time.
Special Report anchor Bret Baier, The Kelly File anchor Megyn Kelly and FOX News Sunday host Chris Wallace will return as moderators for the last contest among the candidates before the Iowa Caucus on February 1, 2016. The criteria for candidate entry to the debate will be declared closer to the date.
Following the debate, FNC will present special live daytime and primetime programming from the Hawkeye state in the days leading up to the Iowa Caucus as the first votes are cast in the 2016 election.
Twenty-First Century Fox, Inc. operates as a diversified media and entertainment company worldwide. It operates through Cable Network Programming; Television; Filmed Entertainment; and Other, Corporate and Eliminations segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.